The positive clinical data provides fundamental support, but the ATM upsizing signals potential dilution ahead. Watch for Phase 3 initiation in Q3 2026 and data readouts in H2 2026; near-term share price may be pressured by the increased overhang from the ATM.
GPCR drugs
GPCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $39.10entry
- T+1 · 6mo ago −1.99%α −2.23% · $38.32
- T+5 · 6mo ago +1.89%α +0.43% · $39.84
- T+20 · 5mo ago −3.89%α −3.91% · $37.58
- T+60 · 3mo ago +26.96%α +22.12% · $49.64
Price Chart
How similar events traded
Executive Summary
Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening from $46.8M a year ago, while announcing positive Phase 2 aleniglipron data (16.3% weight loss at 44 weeks) and FDA end-of-Phase 2 feedback. The company also upsized its ATM offering to $400M (from $250M), adding $150M in potential dilution. The clinical progress is offset by rising losses and capital raise, resulting in a mixed outlook.
Key Facts
- Positive Phase 2 ACCESS II data: placebo-adjusted mean weight loss of 16.3% with 180 mg dose at 44 weeks
- FDA provided positive end-of-Phase 2 feedback; Phase 3 initiation on track for Q3 2026
- Q1 2026 net loss of $76.0M vs $46.8M in Q1 2025
- Amended ATM sales agreement to increase aggregate offering capacity to $400M (from $250M), $150M added
- Cash and short-term investments of $1.5B as of March 31, 2026, expected to fund operations through end of 2028
- Upcoming catalysts: ACCESS OLE data in Q3 2026, body composition and T2DM data in Q4 2026
Financial Impact
Q1 2026 net loss widened to $76.0 million from $46.8 million year-over-year; no revenue reported. ATM capacity increased by $150 million to $400 million, with $58.5 million already drawn.
Risk Factors
- Dilution from ATM sales of up to $400M in ADSs
- Clinical trial risks in Phase 3 for aleniglipron
- Competition from injectable and oral GLP-1 drugs (e.g., Novo Nordisk, Eli Lilly)
- Increasing R&D expenses without near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-057226 |
| Document: tm2613721d1_ex99-1.htm | 0001104659-26-057226 |
| Document: tm2613721d1_8k.htm | 0001104659-26-057226 |
| Document: tm2613721d1_ex5-1.htm | 0001104659-26-057226 |
| Document: 0001104659-26-057226-index-headers.html | 0001104659-26-057226 |
| Document: 0001104659-26-057226-index.html | 0001104659-26-057226 |
| Document: 0001104659-26-057226.txt | 0001104659-26-057226 |
| 8-K Data (Synthetic) | 0001104659-26-057226 |
Track record
10 reports on GPCR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $21.73 Now $18.57 −14.54% settles Feb 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $19.08 Now $18.57 −2.67% settles Feb 3
- Jun 11, 202622w ago Institutional Cluster Bearish 5/10 Entry $43.30 to $47.34 Now $18.57 +57.11% ▼ −9.33% −4.93% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Viewing Entry $39.10 to $49.64 Now $18.57 −52.51% ▲ +26.96% +22.12% vs SPY
- Apr 27, 202629w ago Press Release Neutral 2/10 Entry $43.56 to $50.80 Now $18.57 −57.37% ▲ +16.62% +12.63% vs SPY
- Apr 15, 202630w ago 8-K Neutral 3/10 Entry $54.25 to $53.36 Now $18.57 −65.77% ▼ −1.64% −9.78% vs SPY
- Mar 16, 202635w ago Press Release Bullish 8/10 Entry $56.65 to $37.77 Now $18.57 −67.22% ▼ −33.33% −43.81% vs SPY
- Feb 28, 202637w ago Institutional Cluster Mixed 6/10 Entry $62.90 to $39.58 Now $18.57 −70.48% ▼ −37.07% −46.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers